Brookline Capital Management Weighs in on QNCX Q2 Earnings

Quince Therapeutics, Inc. (NASDAQ:QNCX) – Analysts at Brookline Capital Management decreased their Q2 2025 earnings per share (EPS) estimates for Quince Therapeutics in a research note issued on Tuesday, May 13th. Brookline Capital Management analyst K. Raja now forecasts that the company will earn ($0.29) per share for the quarter, down from their prior estimate of ($0.24). The consensus estimate for Quince Therapeutics’ current full-year earnings is ($1.21) per share. Brookline Capital Management also issued estimates for Quince Therapeutics’ Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.07) EPS, FY2026 earnings at ($0.82) EPS, FY2027 earnings at ($0.49) EPS, FY2028 earnings at $0.08 EPS and FY2029 earnings at $0.46 EPS.

QNCX has been the subject of several other reports. D. Boral Capital decreased their price objective on shares of Quince Therapeutics from $12.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, March 25th. Oppenheimer began coverage on shares of Quince Therapeutics in a research note on Monday, March 24th. They set an “outperform” rating and a $10.00 price target on the stock. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $8.00.

Quince Therapeutics Price Performance

Shares of NASDAQ QNCX opened at $0.84 on Friday. Quince Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.45. The company has a market cap of $37.02 million, a PE ratio of -0.68 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. The business has a 50-day simple moving average of $1.17 and a two-hundred day simple moving average of $1.51.

Quince Therapeutics (NASDAQ:QNCX) last announced its earnings results on Tuesday, May 13th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10).

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Ieq Capital LLC acquired a new position in Quince Therapeutics in the 1st quarter worth approximately $1,073,000. Geode Capital Management LLC boosted its holdings in shares of Quince Therapeutics by 10.9% in the 4th quarter. Geode Capital Management LLC now owns 375,932 shares of the company’s stock valued at $703,000 after acquiring an additional 36,807 shares during the last quarter. Shay Capital LLC boosted its holdings in shares of Quince Therapeutics by 60.8% in the 4th quarter. Shay Capital LLC now owns 276,799 shares of the company’s stock valued at $518,000 after acquiring an additional 104,616 shares during the last quarter. Scharf Investments LLC acquired a new stake in shares of Quince Therapeutics in the fourth quarter worth $170,000. Finally, Intellectus Partners LLC purchased a new position in shares of Quince Therapeutics during the first quarter worth $71,000. 30.75% of the stock is currently owned by hedge funds and other institutional investors.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.